Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents01:29

Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents

300
Crohn's disease is an inflammatory bowel disorder marked by chronic inflammation of the GI tract. Various treatment strategies for Crohn's disease are employed, such as immunomodulatory agents, glucocorticoids, and biologics or anti-TNF therapy. Azathioprine (Imuran), a commonly used immunomodulatory drug for Crohn's disease, is converted in the body to mercaptopurine, which inhibits purine biosynthesis and cell proliferation. Both are utilized in severe cases of Inflammatory Bowel...
300
Tumor Immunotherapy01:27

Tumor Immunotherapy

801
Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.
801
Drugs for Treatment of Crohn's Disease in IBD Using Glucocorticoids01:21

Drugs for Treatment of Crohn's Disease in IBD Using Glucocorticoids

266
Glucocorticoids, a class of anti-inflammatory drugs, are pivotal in treating moderate to severe Crohn's disease by inducing remission. They exhibit their anti-inflammatory action by inhibiting the production of inflammatory cytokines such as tumor necrosis factor (TNF)-α, interleukin (IL)-1, and chemokines like IL-8. In addition, they reduce the expression of inflammatory cell adhesion molecules and inhibit gene transcription of nitric oxide synthase, phospholipase A2, cyclooxygenase-2...
266
Immunodeficiency Diseases01:25

Immunodeficiency Diseases

1.4K
Immunodeficiency disorders are conditions in which the immune system's ability to fight infectious disease and cancer is compromised or entirely absent. The immune system comprises a complex network of cells, tissues, and organs that work together to protect the body from potentially harmful invaders. When this system is deficient or not functioning properly, it leaves the body susceptible to infections, diseases, or other complications.
There are three main causes of immunodeficiency...
1.4K
Cell-mediated Immune Responses01:40

Cell-mediated Immune Responses

78.8K
Overview
78.8K
Drugs for Treatment of Ulcerative Colitis in IBD01:29

Drugs for Treatment of Ulcerative Colitis in IBD

285
Ulcerative colitis is a chronic inflammatory condition primarily affecting the colon and rectum. The primary drugs used in the treatment of ulcerative colitis are aminosalicylates. They exhibit anti-inflammatory and immunosuppressive properties. They modulate inflammatory mediators and inhibit the activity of nuclear factor κB (NF-κB). Aminosalicylates also reduce inflammation by inhibiting prostaglandin and leukotriene production and decreasing neutrophil chemotaxis and superoxide...
285

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

[A case of neuronal intranuclear inclusion disease diagnosed 19 years after onset through clinical re-evaluation].

Rinsho shinkeigaku = Clinical neurology·2025
Same author

Immunological and therapeutic insights in autoimmune autonomic ganglionopathy: What is the position of apheresis in immunotherapy?

Transfusion and apheresis science : official journal of the World Apheresis Association : official journal of the European Society for Haemapheresis·2024
Same author

The Presence of Ganglionic Acetylcholine Receptor Antibodies in Sera from Patients with Functional Gastrointestinal Disorders: A Preliminary Study.

Journal of personalized medicine·2024
Same author

[Lambert-Eaton Myasthenic Syndrome].

Brain and nerve = Shinkei kenkyu no shinpo·2024
Same author

Evaluation of cell adhesion molecules (LFA-1 and L-selectin) in ankylosing spondylitis patients after treatment with β-D-mannuronic acid (M2000).

The Indian journal of medical research·2023
Same author

Immunotherapy for ocular myasthenia gravis: an observational study in Japan.

Therapeutic advances in neurological disorders·2023

Related Experiment Video

Updated: Nov 5, 2025

In Vitro and In Vivo Assessment of T, B and Myeloid Cells Suppressive Activity and Humoral Responses from Transplant Recipients
18:48

In Vitro and In Vivo Assessment of T, B and Myeloid Cells Suppressive Activity and Humoral Responses from Transplant Recipients

Published on: August 12, 2017

14.6K

[Immunosuppressive Treatment].

Hidenori Matsuo1

  • 1National Nagasaki Hospital, National Hospital Organization.

Brain and Nerve = Shinkei Kenkyu No Shinpo
|May 19, 2021
PubMed
Summary

Immunosuppressive cytotoxic agents offer an alternative for central nervous system autoimmune diseases unresponsive to standard therapies. Careful patient selection and monitoring are crucial due to potential serious side effects and opportunistic infections.

Area of Science:

  • Neurology
  • Immunology
  • Pharmacology

Background:

  • Central nervous system (CNS) autoimmune/inflammatory diseases pose significant challenges.
  • Steroids, plasmapheresis, and intravenous immunoglobulin (IVIG) are primary treatments.
  • Some cases remain refractory to these initial interventions.

Purpose of the Study:

  • To evaluate the role of immunosuppressive (cytotoxic) agents in refractory CNS autoimmune/inflammatory diseases.
  • To highlight the importance of informed consent and risk-benefit assessment.

Main Methods:

  • Review of clinical data for patients with CNS autoimmune/inflammatory diseases treated with cytotoxic agents.
  • Analysis of treatment response and adverse events.

Main Results:

More Related Videos

Quantification of the Immunosuppressant Tacrolimus on Dried Blood Spots Using LC-MS/MS
08:38

Quantification of the Immunosuppressant Tacrolimus on Dried Blood Spots Using LC-MS/MS

Published on: November 8, 2015

17.1K
Murine Full-thickness Skin Transplantation
07:59

Murine Full-thickness Skin Transplantation

Published on: January 2, 2017

20.7K

Related Experiment Videos

Last Updated: Nov 5, 2025

In Vitro and In Vivo Assessment of T, B and Myeloid Cells Suppressive Activity and Humoral Responses from Transplant Recipients
18:48

In Vitro and In Vivo Assessment of T, B and Myeloid Cells Suppressive Activity and Humoral Responses from Transplant Recipients

Published on: August 12, 2017

14.6K
Quantification of the Immunosuppressant Tacrolimus on Dried Blood Spots Using LC-MS/MS
08:38

Quantification of the Immunosuppressant Tacrolimus on Dried Blood Spots Using LC-MS/MS

Published on: November 8, 2015

17.1K
Murine Full-thickness Skin Transplantation
07:59

Murine Full-thickness Skin Transplantation

Published on: January 2, 2017

20.7K
  • Cytotoxic agents demonstrate efficacy in select cases unresponsive to conventional therapies.
  • Significant potential for serious side effects necessitates careful management.

Conclusions:

  • Immunosuppressive cytotoxic agents represent a viable therapeutic option for refractory CNS autoimmune/inflammatory conditions.
  • Proactive management of side effects and opportunistic infections is paramount for patient safety.